z-logo
Premium
Pradofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial
Author(s) -
Mueller Ralf S.,
Stephan Bernd
Publication year - 2007
Publication title -
veterinary dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.744
H-Index - 60
eISSN - 1365-3164
pISSN - 0959-4493
DOI - 10.1111/j.1365-3164.2007.00584.x
Subject(s) - medicine , clavulanic acid , amoxicillin , pyoderma , randomized controlled trial , clinical trial , lesion , gastroenterology , surgery , antibiotics , dermatology , biology , microbiology and biotechnology
A multicentre, randomized, blinded study compared the efficacy of pradofloxacin with that of a combination of amoxycillin/clavulanic acid in the treatment of deep pyoderma in dogs. Dogs with clinical lesions of deep pyoderma and a positive bacterial culture were included in the study. At each visit, they were evaluated with lesion, pruritus and general condition scores. Dogs were treated either with pradofloxacin at 3 mg kg −1 once daily or with amoxycillin at 10 mg kg −1 and clavulanic acid at 2.5 mg kg −1 twice daily and evaluated weekly for 3 weeks and every 2 weeks thereafter until 2 weeks past clinical remission. Maximal treatment duration was 9 weeks, and maximal evaluation period was 11 weeks. Of the 56 dogs treated with pradofloxacin (group 1), 48 dogs (86%) achieved clinical remission, four dogs improved, four dogs did not respond and a recurrence of clinical signs was not seen in any patient after 11 weeks. Of the 51 dogs treated with amoxycillin/clavulanic acid (group 2), 37 dogs achieved clinical remission (73%), three dogs showed improvement, five dogs showed no response and in six dogs, clinical signs recurred within 2 weeks of cessation of therapy. These results indicate that pradofloxacin is an efficacious therapy comparable to amoxycillin/clavulanic acid for deep bacterial pyoderma in dogs.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here